Potential biomarker emerging for diabetic neuropathy

June 13, 2012
Nervous system

An emerging biomarker may eventually lead to new approaches for treating diabetics at risk of developing nerve damage, UNSW researchers have found.

The researchers say neuropathy in is under-diagnosed and early identification has been problematic. It is estimated that up to 50 per cent of diabetics end up with nerve damage.

They tested excitability in diabetics with and without neuropathy and found those without irreversible still showed excitability abnormalities well before the development of clinical symptoms.

“Excitability testing provides a to identify the early development and severity of diabetic neuropathy,” the key researcher Dr Cindy Lin said.

The research was led by UNSW and the School of Medical Science’s Dr Cindy Lin and is published in the journal Diabetes.

Professor Matthew Kiernan from UNSW says the research may lead to new therapeutic approaches for treating patients with diabetic neuropathy early.

“It may yet prove possible to initiate therapy in diabetic patients well before they manifest the neurological symptoms and disability that inevitably reflects the presence clinical neuropathy,” Professor Kiernan says in his commentary, also published in Diabetes.

“Pharmacological manipulation of axonal membrane channels seems likely to provide further new therapeutic approaches for treating patients with diabetic neuropathy,” he says.

Explore further: Bone marrow cells can heal nerves in diabetes model

Related Stories

Bone marrow cells can heal nerves in diabetes model

February 4, 2009

Transplanting cells that replenish blood vessels can also restore nerve function in an animal model of diabetic neuropathy, Emory researchers have found. The results are described online this week in the journal Circulation.

Recommended for you

New study reveals a novel protein linked to type 2 diabetes

August 16, 2016

Findings from Boston University School of Medicine (BUSM), which appear in eLife, provide a possible explanation as to why most people who are obese develop insulin resistance and type 2 diabetes. A minority of obese individuals, ...

Gene variant explains differences in diabetes drug response

August 9, 2016

The first results from a large international study of patients taking metformin, the world's most commonly used type 2 diabetes drug, reveal genetic differences among patients that may explain why some respond much better ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.